Covishield vaccine can result in bleeding problems

The researchers on Wednesday stated that people who are getting the Covid vaccine that Oxford AstraZeneca has developed, Covishield in India has a tendency to develop bleeding problems and other rare blood disorders.

The study conducted on 2.53 million people in Scotland was published in the journal Nature Medicine. This group of people either got the AstraZeneca vaccine or the Pfizer-BioNTech vaccine. Nearly 1.7 million doses were the AstraZeneca one.

There was no incident of blood problem with the Pfizer-BioNTech vaccine.

The AstraZeneca vaccine did not get approval for usage in the United States but the European Medicines Agency, the European Union’s famous drug regulator, and many countries outside the bloc authorized it. But the incidents of clotting and bleeding problems in the younger generation, some of them who have died, prompted the countries to restrict the use of the vaccine on older people.

A recent study pointed out that the AstraZeneca vaccine can result in an increase in the risk of a disorder named immune thrombocytopenic purpura or ITP that leads to bruising in some cases and serious bleeding in other cases. The risk was deemed to be 1.13 cases per 100,000 people who got the first dose of the vaccine, up to 27 days of vaccination.

Such a condition can be treated and no people who have received the vaccine have died, as per the researchers. They stressed that the positive side of the vaccine surpassed such a petty risk.

The researchers stated that in spite of the risk from the AstraZeneca vaccine being petty, “alternative vaccine for individuals at low Covid-19 risk might be warranted when supply allows.”

The researchers opined that determining ITP in few vaccinated people isn’t unnatural. Such a risk is also associated with the vaccines related to measles, mumps, and rubella and also for hepatitis B and flu.